SMG vs AMGN

For growth investors, Amgen Inc.

(AMGN) is the stronger pick with 9. 9% revenue growth year-over-year, versus -3. 9% for The Scotts Miracle-Gro Company (SMG). Amgen Inc. (AMGN) offers the better valuation at 23. 1x trailing P/E (14. 7x forward), making it the more compelling value choice. Analysts rate The Scotts Miracle-Gro Company (SMG) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Amgen Inc.

(AMGN) is the cheapest at 23. 1x versus The Scotts Miracle-Gro Company at 25. 3x. On forward P/E, The Scotts Miracle-Gro Company is actually cheaper at 14. 2x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Amgen Inc.

(AMGN) delivered a total return of +46. 2%, compared to -69. 1% for The Scotts Miracle-Gro Company (SMG). Over 10 years, the gap is even starker: AMGN returned +156. 4% versus SMG's +34. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Amgen Inc.

(AMGN) is the lower-risk stock at 0. 60β versus The Scotts Miracle-Gro Company's 1. 10β — meaning SMG is approximately 83% more volatile than AMGN relative to the S&P 500.

By revenue growth (latest reported year), Amgen Inc.

(AMGN) is pulling ahead at 9. 9% versus -3. 9% for The Scotts Miracle-Gro Company (SMG). On earnings-per-share growth, the picture is similar: The Scotts Miracle-Gro Company grew EPS 504. 9% year-over-year, compared to 88. 2% for Amgen Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus 4. 3% for The Scotts Miracle-Gro Company — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: AMGN leads at 29. 1% versus 10. 5% for SMG. At the gross margin level — before operating expenses — AMGN leads at 70. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, The Scotts Miracle-Gro Company (SMG) trades at 14.

2x forward P/E versus 14. 7x for Amgen Inc. — 0. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SMG: 15. 4% to $72. 00.

All stocks in this comparison pay dividends.

The Scotts Miracle-Gro Company (SMG) offers the highest yield at 4. 2%, versus 2. 9% for Amgen Inc. (AMGN).

For long-horizon retirement investors, Amgen Inc.

(AMGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 60), 2. 9% yield, +156. 4% 10Y return). Both have compounded well over 10 years (AMGN: +156. 4%, SMG: +34. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (SMG (Basic Materials) and AMGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: SMG is a small-cap income-oriented stock; AMGN is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.